Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Migraine Drugs Market

Migraine Drugs Market Share

Report ID: GMI9899
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Migraine Drugs Market Share

The competitive landscape of the migraine drugs industry is characterized by the presence of established pharmaceutical companies that manufacture migraine drugs products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for migraine drugs.

Migraine Drugs Market Companies

Prominent players operating in the migraine drugs industry are as mentioned below:

AbbVie Inc.
Amgen, Inc.
Astellas Pharma
AstraZeneca Plc
Azurity Pharmaceutical, Inc.
Dr. Reddy’s Laboratories, Inc.
Eli Lilly and Company
Endo Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Lannett Company, Inc.
Lundbeck A/S
Pfizer, Inc.
Sanofi SA
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Global migraine drugs industry was valued at USD 6.2 billion in 2023 and is anticipated to register 6.7% CAGR between 2024 and 2032 due to the increasing incidence and prevalence of migraine along with growing awareness and diagnosis of migraine.

The hospital pharmacies segment in the market is anticipated to reach USD 4.9 billion by 2032, driven by increasing migraine cases needing specialized care, diverse drug offerings, and inpatient management of severe attacks,

North America migraine drugs market held 41.5% revenue share in 2023 due to advanced healthcare infrastructure, effective awareness campaigns, high diagnosis rates, and substantial healthcare spending.

AbbVie Inc., Amgen, Inc., Astellas Pharma, AstraZeneca Plc, Azurity Pharmaceutical, Inc., Dr. Reddy